As "best guesses" based upon very little in the way of hard facts are of value to some here, my best guess is that you are probably correct in your prediction of an imminent rise in the share price to $10.
It seems to me that all that really stands between us and a share price somewhere above $50 is the uncertainty embodied in the dog toxicity study due to be completed in January.
What's the earliest date by which some people will know if the data is clean?
A great many investors will be too risk-averse to buy shares until they know for sure that the final potential drug safety pitfall is no longer there. But I'm certain that the potential of Arikace is on such a scale that there will be massive demand for the shares when that uncertainty has been resolved.
The implications for substantial share price appreciation at that point are such that INSM represents a very tempting gamble at this point.
The potential buyers are currently holding off, hoping to nullify the perception that they will be prepared to pay over $10 a share. I'm guessing they have a window of around three months in which to manoeuver - but the closer we get to a potential leak of the results, the more tempting will be the argument to grab some cheap shares before the rest of the "gamblers" make their move.
You'd be more convincing as a Brit is you spelled "manoeuvre" correctly.
Just another one of your many lies.
As to your earlier posting about Ayers, fiscal cliff and all that. Don't you think that Ayers was thinking of the fiscal cliff when they sold? So, yes, the ol' cliff was involved. And, anyone that is paying attention is moving equity to cash at some level or another.